Our founding principle
Founded on
a single belief.
That the appearance of our skin need not reflect our chronological age. When the biology beneath the skin is properly supported — when cellular communication is restored, the barrier is fortified, and the skin’s environment is calm — visible improvement follows.
Not in one area. In many, simultaneously.
This is the principle that EXOGLO was built around. And it is the reason MESCH exists.
The origin
A question asked in the laboratory.
MESCH began with a research question: could the biology of exosomes — the cell-to-cell communication system at the centre of regenerative medicine — be applied directly to the surface of skin?
The answer, after years of research, formulation trials, and validation alongside leading chemists in Tokyo, became EXOGLO Serum. The first product from a biotechnology company that treats skincare with the rigour of clinical science — because it always has been.
Not a skincare brand that borrowed scientific language. A science company that made a skincare product.
Executive Leadership
Christopher
Mesh
Chief Executive Officer & Co-founder
MESCH
Christopher Mesh merges innovation, strategy, and a deep understanding of human connection to position MESCH at the forefront of longevity sciences — ensuring that what the laboratory makes possible reaches the people it was designed for.
Scientific Leadership
Dr. Joshua
Chou, PhD
Scientific Director, MESCH
Associate Professor, University of Technology Sydney
Biomedical Engineering & Exosome Biology
Dr. Joshua Chou’s research spans biomedical engineering, exosome biology, and the science of cellular ageing — areas that have historically existed far from skincare. At MESCH, that distance is the point.
His laboratory at the University of Technology Sydney pioneered the use of human adipose-derived mesenchymal stem cell exosomes in topical applications. This research — which had previously existed exclusively within the domain of regenerative medicine — now forms the scientific foundation of EXOGLO Serum.
The formulation process behind EXOGLO was not a matter of selecting trendy actives. It was a matter of establishing the biological conditions under which healthy-looking skin becomes possible — and then engineering a product that creates those conditions consistently, every morning and night.
- Research Focus
- Exosome biology, biomedical engineering, cellular ageing
- Institution
- University of Technology Sydney
- Formulation Partners
- Leading cosmetic chemists, Tokyo, Japan
- Validation Partner
- EVELAB AI Skin Analysis
Commercial Leadership
Tommy
Yan
Chief Commercial Officer & Co-founder
MESCH
Tommy Yan is a seasoned strategist and marketing expert who played a pivotal role in the founding of MESCH. As Chief Commercial Officer he also leads MESCH’s Marketing and People efforts. He combines business acumen with creative insight to shape MESCH’s brand identity and long-term growth strategies. Tommy has helped position MESCH as a leader in longevity sciences.
Our approach
Three principles
that guide everything
we make.
-
Clinical
RigourEvery formulation decision at MESCH is grounded in biomedical research. We do not add ingredients because they are fashionable. We add them because the science supports their mechanism — and because we can measure their effect. EXOGLO was not designed to feel luxurious. It was designed to work. That it also feels exceptional is a consequence of getting the biology right.
-
Biological
IntelligenceThe skin is not a surface to be treated. It is a complex, living system — with its own communication pathways, protective mechanisms, and environmental sensitivities. EXOGLO was formulated to work with this system, not to override it. Microbiome-conscious pH, barrier-supporting lipids, and exosome-based cellular signalling: every component chosen because it supports what healthy skin already knows how to do.
-
Measured
AccountabilityIn partnership with EVELAB, MESCH uses advanced skin imaging and artificial intelligence to evaluate the visible effects of EXOGLO over time. We do not rely on claimed outcomes. We measure them — across 35 skin attributes, with an AI trained on more than 10 million skin images and validated by dermatologists and microbiome researchers.
Crafted in Tokyo, Japan
Where science
meets formulation.
EXOGLO is formulated in Tokyo — a city whose cosmetic manufacturing tradition sets the global benchmark for precision, hygiene, and stability science.
Working alongside leading cosmetic chemists with deep expertise in bioactive formulation, MESCH developed EXOGLO to meet the exact requirements of both its biological actives and the skin that receives them.
The result is a lightweight gel-serum that delivers exosome technology in a form the skin can absorb — stable, sensorial, and formulated to the highest standards of cosmetic science.
- Manufacturing
- Tokyo, Japan
- pH
- 5.5 — Microbiome-conscious
- Texture
- Lightweight gel-serum
- Scent
- Yuzu essential oil
AI Skin Assessment
35 skin attributes.
10 million images.
Zero guessing.
- 35
- Skin attributes analysed by EVELAB’s AI — from texture and tone to barrier integrity and microbiome balance.
- 10M+
- Skin images used to train and validate the EVELAB AI model, verified by leading dermatologists and environmental medicine specialists.
In partnership with EVELAB, MESCH uses advanced skin imaging and artificial intelligence to evaluate the visible effects of EXOGLO over time. Rather than relying on subjective assessments or self-reported outcomes, EVELAB uses standardised imaging protocols and AI-driven analysis to assess change across a defined set of skin attributes.
The methodology is validated by dermatologists, environmental medicine specialists, and microbiome researchers. It is the same standard MESCH holds itself to internally — and the same standard we believe the skincare industry should adopt broadly.
EVELAB methodology →
Science you can see in the mirror.
The first innovation from MESCH
EXOGLO Serum
Exosome serum.
Formulated in Tokyo, Japan.